Pfizer and BioNTech Have Developed a Covid-19 Vaccine with a 90% Success Rate

Pfizer and BioNTech Have Developed a Covid-19 Vaccine with a 90% Success Rate

Pfizer and BioNTech Have Developed a Covid-19 Vaccine with a 90% Success Rate

No other vaccine has proven to be highly effective in such a short period of time.

The vaccine developed by Pfizer and BioNTech has been tested on 43,500 people in 6 countries.

All trials took place in the United States, Turkey, Germany, Argentina, Brazil and South Africa.

The vaccine has achieved 90% protection 7 days after the second dose.

In addition, no safety concerns have been raised so far.

There are still huge challenges ahead as the virus is still mutating. 

A Covid-19 vaccine is seen as the best solution to get out of the lockdowns that have been imposed all over the world.

Pfizer aims to supply 50 million doses by the end of 2020.

The United Kingdom has already ordered 30 million doses, while the United States paid $1.95 billion for 100 million initial doses.

It's important to state that there are some logistical challenges ahead, as the Covid-19 vaccine must be kept in ultra-cold storage at below minus 80C.

Healthcare staff, essential workers and those at highest risk from Covid-19 will be prioritised.

 

Arlen Meyers, MD, MBA is the President and CEO of the Society of Physician Entrepreneurs.

 

Share this article

Leave your comments

Post comment as a guest

0
terms and condition.
  • Darren Wiltshire

    If the vaccine has been released last week before the election... the outcome would have been different. Anyways the better man won. 90% success rate shows that this vaccine is promising.

  • Catherine Rhodes

    I knew it that America will be the first one to find a vaccine. China's vaccine isn't safe.

  • Joey Lacon

    How much will they charge us for this vaccine?

  • Hugh Jameson

    Great news

  • Rob Mason

    I had covid in July ! I was ill for a week !

  • Ellen Townley

    Tested negative thrice... I kindly prefer to stay away from a vaccine...

  • Alex Richards

    Informative

  • Jamie Gaughan

    Looks like 2021 is the end of covid.

Share this article

Arlen Meyers, MD, MBA

Healthcare Expert

Arlen Meyers, MD, MBA is a professor emeritus of otolaryngology, dentistry, and engineering at the University of Colorado School of Medicine and the Colorado School of Public Health and President and CEO of the Society of Physician Entrepreneurs at www.sopenet.org. He has created several medical device and digital health companies. His primary research centers around biomedical and health innovation and entrepreneurship and life science technology commercialization. He consults for and speaks to companies, governments, colleges and universities around the world who need his expertise and contacts in the areas of bio entrepreneurship, bioscience, healthcare, healthcare IT, medical tourism -- nationally and internationally, new product development, product design, and financing new ventures. He is a former Harvard-Macy fellow and In 2010, he completed a Fulbright at Kings Business, the commercialization office of technology transfer at Kings College in London. He recently published "Building the Case for Biotechnology." "Optical Detection of Cancer", and " The Life Science Innovation Roadmap". He is also an associate editor of the Journal of Commercial Biotechnology and Technology Transfer and Entrepreneurship and Editor-in-Chief of Medscape. In addition, He is a faculty member at the University of Colorado Denver Graduate School where he teaches Biomedical Entrepreneurship and is an iCorps participant, trainer and industry mentor. He is the Chief Medical Officer at www.bridgehealth.com and www.cliexa.com and Chairman of the Board at GlobalMindED at www.globalminded.org, a non-profit at risk student success network. He is honored to be named by Modern Healthcare as one of the 50 Most Influential Physician Executives of 2011 and nominated in 2012 and Best Doctors 2013.

   

Latest Articles

View all
  • Science
  • Technology
  • Companies
  • Environment
  • Global Economy
  • Finance
  • Politics
  • Society